Please use this identifier to cite or link to this item: https://hdl.handle.net/10356/141828
Title: Proof-of-concept preparation and characterization of dual-drug amorphous nanoparticle complex as fixed-dose combination of poorly soluble drugs
Authors: Yu, Hong
Lim, Li Ming
Dong, Bingxue
Hadinoto, Kunn
Keywords: Engineering::Chemical engineering
Issue Date: 2019
Source: Yu, H., Lim, L. M., Dong, B. & Hadinoto, K. (2019). Proof-of-concept preparation and characterization of dual-drug amorphous nanoparticle complex as fixed-dose combination of poorly soluble drugs. Drug Development and Industrial Pharmacy, 45(1), 105-116. https://dx.doi.org/10.1080/03639045.2018.1522327
Journal: Drug Development and Industrial Pharmacy
Abstract: Objectives: To carry out a proof-of-concept study on the development of dual-drug amorphous nanoparticle complex (nanoplex in short) as a potential formulation platform for fixed-dose combination (FDC) of poorly-soluble drugs. Significance: FDC has been proven effective in improving patient compliance for treatment that requires complex multidrug regimen. Currently, there is growing interest to develop FDC of poorly-soluble drugs due to the increased number of drugs exhibiting poor solubility thus low bioavailability. Methods: The dual-drug nanoplex was prepared by electrostatically-driven co-complexation of drug molecules with oppositely charged dextran sulfate, using ciprofloxacin (CIP) and itraconazole (ITZ) as the model poorly-soluble drugs. Results: We first verified that the co-complexation products were dual-drug CIP-ITZ nanoplex, and not binary mixtures of the single-drug CIP and ITZ nanoplexes, by demonstrating their distinct thermal behaviors and dissolution characteristics. Depending on the preparation condition, the dual-drug nanoplex exhibited size and zeta potential of 160–410 nm and −35–50 mV, respectively. The individual drug payloads were readily manipulated by varying the CIP/ITZ mass ratio in the feed, resulting in CIP and ITZ payloads in the range of 60-30% and 15-45%, respectively. The CIP-ITZ nanoplex, however, exhibited diminished CIP supersaturation generation, thus lower CIP solubility enhancement, compared to the single-drug CIP nanoplex. The CIP-ITZ nanoplex, nonetheless, remained capable of generating high ITZ supersaturation level. Conclusion: Dual-drug nanoplex was successfully prepared with a high degree of control over its physical characteristics. Nevertheless, whether dual-drug nanoplex always exhibits diminished solubility enhancement compared to its single-drug counterparts needs to be investigated using different poorly-soluble drugs.
URI: https://hdl.handle.net/10356/141828
ISSN: 0363-9045
DOI: 10.1080/03639045.2018.1522327
Rights: This is an Accepted Manuscript of an article published by Informa UK Limited, trading as Taylor and Francis in Drug Development and Industrial Pharmacy on 25 Sep 2018, available online: http://www.tandfonline.com/10.1080/03639045.2018.1522327.
Fulltext Permission: open
Fulltext Availability: With Fulltext
Appears in Collections:SCBE Journal Articles

SCOPUSTM   
Citations 50

5
Updated on Nov 29, 2022

Web of ScienceTM
Citations 20

6
Updated on Dec 1, 2022

Page view(s)

190
Updated on Dec 5, 2022

Download(s) 50

30
Updated on Dec 5, 2022

Google ScholarTM

Check

Altmetric


Plumx

Items in DR-NTU are protected by copyright, with all rights reserved, unless otherwise indicated.